1. Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies. (3rd July 2020) Authors: Strober, B.; Menter, A.; Leonardi, C.; Gordon, K.; Lambert, J.; Puig, L.; Photowala, H.; Longcore, M.; Zhan, T.; Foley, P. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 12(2020) Page Start: 2830 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials. (19th November 2019) Authors: van der Zee, H.H.; Longcore, M.; Geng, Z.; Garg, A. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 5(2020) Page Start: 1050 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗